Praziquantel: Too Good to be Replaced?

Parasitic Helminths: Targets, Screens, Drugs and Vaccines

Volumn , Issue , 2012, Pages 309-321

  Pica Mattoccia, Livia ^a   Cioli, Donato ^a  

^a CNR   (Italy)

Author keywords

Calcium channels; Calcium influx; Mechanism of action; Parasite; Praziquantel; Schistosomiasis

Indexed keywords

EID: 84886144724     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527652969.ch19     Document Type: Chapter

References (86)

1. Siebold, C.T. (1853) Ein Beitrag zur Helminthographia humana, aus brieflichen Mittheilungen des Dr. Bilharz in Kairo, nebst Bemerkungen von Prof. Th. v. Siebold. Z.Wiss. Zool., 4, 53-76.
2. Gönnert, R. and Andrews, P. (1977) Praziquantel, a new broad-spectrum antischistosomal agent. Z. Parasitenkd., 52, 129-150.
3. Seubert, J., Pohlke, R., and Loebich, F. (1977) Synthesis and properties of Praziquantel, a novel broad spectrum anthelmintic with excellent activity against Schistosomes and Cestodes. Experientia, 33, 1036-1037.
4. Katz, N., Rocha, R., and Chaves, A. (1979) Preliminary trials with praziquantel in human infections due to Schistosoma mansoni. Bull. World Health Organ., 57, 781-785.
5. Davis, A., Biles, J.E., and Ulrich, A.M. (1979) Initial experiences with praziquantel in the treatment of humaninfections due to Schistosoma haematobium. Bull. World Health Organ., 57, 773-779.
6. Ishizaki, T., Kamo, E., and Boehme, K. (1979) Double-blind studies of tolerance to praziquantel in Japanese patients with Schistosoma japonicum infections. Bull. World Health Organ., 57, 787-791.
7. Reich, M.R. and Govindaraj, R. (1998) Dilemmas in drug development for tropical diseases. Experiences with praziquantel. Health Policy, 44, 1-18.
8. Fenwick, A., Savioli, L., Engels, D., Bergquist, N.R., and Todd, M.H. (2003) Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol., 19, 509-515.
9. Thomas, H. and Gönnert, R. (1977) The efficacy of praziquantel against cestodes in animals. Z. Parasitenkd., 52, 117-127.
10. Doenhoff, M.J. and Pica-Mattoccia, L. (2006) Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance. Expert Rev. Anti Infect. Ther., 4, 199-210.
11. Xiao, S.H., Catto, B.A., and Webster, L.T. (1985) Effects of praziquantel on different developmental stages of Schistosoma mansoni in vitro and in vivo. J. Infect. Dis., 151, 1130-1137.
12. Sabah, A.A., Fletcher, C., Webbe, G., and Doenhoff, M.J. (1986) Schistosoma mansoni: chemotherapy of infections of different ages. Exp.Parasitol., 61, 294-303.
13. Pica-Mattoccia, L. and Cioli, D. (2004) Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment. Int. J. Parasitol., 34, 527-533.
14. Gryseels, B., Mbaye, A., De Vlas, S.J., Stelma, F.F., Guisse, F., Van Lieshout, L., Faye, D. et al. (2001) Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence. Trop. Med. Int. Health, 6, 864-873.
15. Barakat, R. and Morshedy, H.E. (2011) Efficacy of two praziquantel treatments among primary school children in an area of high Schistosoma mansoni endemicity, Nile Delta. Egypt. Parasitol., 138, 440-446.
16. Stelma, F.F., Talla, A., Sow, S., Kongs, A., Niang, M., Polman, K., Deelder, A.M., and Gryseels, B. (1995) Efficacy and sideeffects of praziquantel in an epidemic focus of Schistosoma mansoni. Am. J. Trop. Med. Hyg., 53, 167-170.
17. Renganathan, E. and Cioli, D. (1998) An international initiative on praziquantel use. Parasitol. Today, 14, 390-391.
18. N.Goran, E.K., Gnaka, H.N., Tanner, M., and Utzinger, J. (2003) Efficacy and sideeffects of two praziquantel treatments against Schistosoma haematobium infection, among schoolchildren from Côte d.Ivoire. Ann. Trop. Med. Parasitol., 97, 37-51.
19. Doenhoff, M.J. (1998) Is schistosomicidal chemotherapy sub-curative? Implications for drug resistance. Parasitol. Today, 14, 434-435.
20. Hotez, P.J. and Fenwick, A. (2009) Schistosomiasis in Africa: an emerging tragedy in our new global health decade. PLoS Negl. Trop. Dis., 3, e485.
21. Hudson, A. and Nwaka, S. (2007) The concept paper on the helminth drug initiative. Onchocerciasis/lymphatic filariasis and schistosomiasis: opportunities and challenges for the discovery of new drugs/diagnostics. Expert Opin. Drug Discov., 2 (Suppl. 1), S3-S7.
22. Cioli, D. (2000) Praziquantel: is there real resistance and are there alternatives? Curr. Opin. Infect. Dis., 13, 659-663.
23. Stelma, F.F., Sall, S., Daff, B., Sow, S., Niang, M., and Gryseels, B. (1997) Oxamniquine cures Schistosoma mansoni infection in a focus in which cure rates with praziquantel are unusually low. J. Infect. Dis., 176, 304-307.
24. Fallon, P.G., Sturrock, R.F., Capron, A., Niang, M., and Doenhoff, M.J. (1995) Short report: diminished susceptibility to praziquantel in a Senegal isolate of Schistosoma mansoni. Am. J. Trop. Med. Hyg., 53, 61-62.
25. Ismail, M., Metwally, A., Farghaly, A., Bruce, J., Tao, L.F., and Bennett, J.L. (1996) Characterization of isolates of Schistosoma mansoni from Egyptian villagers thattolerate high doses of praziquantel. Am. J. Trop. Med. Hyg., 55, 214-218.
26. Ismail, M., Botros, S., Metwally, A., William, S., Farghally, A., Tao, L.F., Day, T.A., and Bennett, J.L. (1999) Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am. J. Trop. Med. Hyg., 60, 932-935.
27. Fallon, P.G. and Doenhoff, M.J. (1994) Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. Am. J. Trop. Med. Hyg., 51, 83-88.
28. Pica-Mattoccia, L., Doenhoff, M.J., Valle, C., Basso, A., Troiani, A.R., Liberti, P., Festucci, A. et al. (2009)Genetic analysis of decreased praziquantel sensitivity in a laboratory strain of Schistosoma mansoni. Acta Trop., 111, 82-85.
29. Cioli, D., Botros, S.S., Wheatcroft-Francklow, K., Mbaye, A., Southgate, V., Tchuem Tchuente, L.-A., Pica-Mattoccia, L. et al. (2004) Determination of ED50 values for praziquantel in praziquantel-resistant and -susceptible Schistosoma mansoni isolates. Int. J. Parasitol., 34, 979-987.
30. Sabra, A.N. and Botros, S.S. (2008) Response of Schistosoma mansoni isolates having different drug sensitivity to praziquantel over several life cycle passages with and without therapeutic pressure. J. Parasitol., 94, 537-541.
31. Black, C.L., Steinauer, M.L., Mwinzi, P.N., Secor, W.E., Karanja, D.M., and Colley, D.G. (2009) Impact of intense, longitudinal retreatment with praziquantel on cure rates of schistosomiasis mansoni in a cohort of occupationally exposed adults in western Kenya. Trop.Med. Int.Health, 14, 450-457.
32. Melman, S.D., Steinauer, M.L., Cunningham, C., Kubatko, L.S., Mwangi, I.N., Wynn, N.B.,Mutuku, M.W. et al. (2009) Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Negl. Trop. Dis., 3, e504.
33. Valle, C., Troiani, A.-R., Festucci, A., Pica-Mattoccia, L., Liberti, P., Wolstenholme, A., Francklow, K. et al. (2003) Sequence and level of endogenous expression of calcium channel b-subunits in Schistosoma mansoni displaying different susceptibilities to praziquantel. Mol. Biochem. Parasitol., 130, 111-115.
34. Fallon, P.G., Mubarak, J.S., Fookes, R.E., Niang, M., Butterworth, A.E., Sturrock, R.F., and Doenhoff, M.J. (1997) Schistosoma mansoni: maturation rate and drug susceptibility of different geographic isolates. Exp. Parasitol., 86, 29-36.
35. Guidi, A., Andolina, C.,Makame Ame, S., Albonico, M., Cioli, D., and JumaHaji, H. (2010) Praziquantel efficacy and long-term appraisal of schistosomiasis control in Pemba Island. Trop. Med. Int. Health, 15, 614-618.
36. Tchuem-Tchuenté, L.-A., Shaw, D.J., Polla, L., Cioli, D., and Vercruysse, J. (2004) Efficacy of praziquantel against Schistosoma haematobium infection in children. Am. J. Trop. Med. Hyg., 71, 778-782.
37. Sulaiman, S.M., Traoré, M., Engels, D., Hagan, P., and Cioli, D. (2001) Counterfeit praziquantel. Lancet, 358, 666-667.
38. Botros, S., El-Lakkany, N., Seif el-Din, S.H., Sabra, A.N., and Ibrahim, M. (2011) Comparative efficacy and bioavailability of different praziquantel brands. Exp. Parasitol., 127, 515-521.
39. Botros, S., Sayed, H., Amer, N., El-Ghannam, M., Bennett, J.L., and Day, T.A. (2005) Current status of sensitivity to praziquantel in a focus of potential drug resistance in Egypt. Int. J. Parasitol., 35, 787-791.
40. Gold, H.S. and Moellering, R.C. Jr (1996) Antimicrobial-drug resistance. N. Engl. J. Med., 335, 1445-1453.
41. Hayton, K. and Su, X.Z. (2004) Genetic and biochemical aspects of drug resistance in malaria parasites. Curr. Drug Targets Infect. Disord., 4, 1-10.
42. Day, T.A., Bennett, J.L., and Pax, R.A. (1992) Praziquantel: the enigmatic antiparasitic. Parasitol. Today, 8, 342-344.
43. Caffrey, C.R. (2007) Chemotherapy of schistosomiasis: present and future. Curr. Opin. Chem. Biol., 11, 433-439.
44. Pax, R., Bennett, J.L., and Fetterer, R. (1978) A benzodiazepine derivative and praziquantel: effects on musculature of Schistosoma mansoni and Schistosoma japonicum. Naunyn Schmiedebergs Arch. Pharmacol., 304, 309-315.
45. Becker, B., Mehlhorn, H., Andrews, P., Thomas, H., and Eckert, J. (1980) Light and electron microscopic studies on the effect of praziquantel on Schistosoma mansoni, Dicrocoelium dendriticum, and Fasciola hepatica (Trematoda) in vitro. Z. Parasitenkd., 63, 113-128.
46. Fetterer, R.H., Pax, R.A., and Bennett, J.L. (1980) Praziquantel, potassium and 2,4-dinitrophenol: analysis of their action on the musculature of Schistosoma mansoni. Eur. J. Pharmacol., 64, 31-38.
47. Pica-Mattoccia, L., Valle, C., Basso, A., Troiani, A.-R., Vigorosi, F., Liberti, P., Festucci, A., and Cioli, D. (2007) Cytochalasin D abolishes the schistosomicidal activity of praziquantel. Exp. Parasitol., 115, 344-351.
48. Kohn, A.B., Anderson, P.A., Roberts-Misterly, J.M., and Greenberg, R.M. (2001) Schistosome calcium channel beta subunits. Unusual modulatory effects and potential role in the action of the antischistosomal drug praziquantel. J. Biol. Chem., 276, 36873-36876.
49. Kohn, A.B., Roberts-Misterly, J.M., Anderson, P.A., Khan, N., and Greenberg, R.M. (2003) Specific sites in the beta interaction domain of a schistosome Ca2{thorn} channel beta subunit are key to its role in sensitivity to the anti-schistosomal drug praziquantel. Parasitology, 127, 349-356.
50. Kohn, A.B., Roberts-Misterly, J.M., Anderson, P.A., and Greenberg, R.M. (2003) Creation by mutagenesis of a mammalian Ca2{thorn} channel beta subunit that confers praziquantel sensitivity to a mammalian Ca2{thorn} channel. Int. J. Parasitol., 33, 1303-1308.
51. Greenberg, R.M. (2005) Are Ca2{thorn} channels targets of praziquantel action? Int. J. Parasitol., 35, 1-9.
52. Jeziorski, M.C. and Greenberg, R.M. (2006) Voltage-gated calcium channel subunits from platyhelminths: potential role in praziquantel action. Int. J. Parasitol., 36, 625-632.
53. Nogi, T., Zhang, D., Chan, J.D., and Marchant, J.S. (2009) A novel biological activity of praziquantel requiring voltageoperated Ca2{thorn} channel beta subunits: subversion of flatworm regenerative polarity. PLoS Negl. Trop. Dis., 3, e464.
54. Pica-Mattoccia, L., Orsini, T., Basso, A., Festucci, A., Liberti, P., Guidi, A., Marcatto-Maggi, A.-L. et al. (2008) Schistosoma mansoni: lack of correlation between praziquantel-induced intraworm calcium influx and parasite death. Exp. Parasitol., 119, 332-335.
55. Mendonça-Silva, D.L., Novozhilova, E., Cobbett, P.J., Silva, C.L., Noel, F., Totten, M.I., Maule, A.G., and Day, T.A. (2006) Role of calcium influx through voltage-operated calcium channels and of calcium mobilization in the physiology of Schistosoma mansoni muscle contractions. Parasitology, 133, 67-74.
56. William, S. and Botros, S. (2004) Validation of sensitivity to praziquantel using Schistosoma mansoni worm muscle tension and Ca2{thorn} uptake as possible in vitro correlates to in vivo ED50 determination. Int. J. Parasitol., 34, 971-977.
57. Angelucci, F., Basso, A., Bellelli, A., Brunori, M., Pica-Mattoccia, L., and Valle, C. (2007) The anti-schistosomal drug praziquantel is an adenosine antagonist. Parasitology, 134, 1215-1221.
58. Tallima, H. and El Ridi, R. (2007) Praziquantel binds Schistosoma mansoni adult worm actin. Int. J. Antimicrob. Agents, 29, 570-575.
59. Tallima, H. and El Ridi, R. (2007) Re: Is actin the praziquantel receptor? Int. J. Antimicrob. Agents, 30, 566-567.
60. Gnanasekar, M., Salunkhe, A.M., Mallia, A.K.,He, Y.K., and Ramaswamy, K. (2009) Praziquantel affects the regulatory myosin light chain of Schistosoma mansoni. Antimicrob. Agents Chemother., 53, 1054-1060.
61. Troiani, A.R., Pica-Mattoccia, L., Valle, C., Cioli, D., Mignogna, G., Ronketti, F., andTodd, M. (2007) Is actin the praziquantel receptor? Int. J. Antimicrob. Agents, 30, 280-281.
62. McTigue, M.A., Williams, D.R., and Taine, J.A. (1995) Crystal structures of a schistosomal drug and vaccine target: glutathione S-transferase from Schistosoma japonica and its complex with the leading antischistosomal drug praziquantel. J. Mol. Biol., 246, 21-27.
63. Milhon, J.L., Thiboldeaux, R.L., Glowac, K., and Tracy, J.W. (1997) Schistosoma japonicum GSH S-transferase Sj26 is not the molecular target of praziquantel action. Exp. Parasitol., 87, 268-274.
64. Wiest, P.M., Li, Y., Olds, R., and Bowen, W.D. (1992) Inhibition of phosphoinositide turnover by praziquantel in Schistosoma mansoni. J. Parasitol., 78, 753-755.
65. Harder, A., Goossens, J., and Andrews, P. (1988) Influence of praziquantel andCa2{thorn} on the bilayer-isotropic-hexagonal transition of model membranes. Mol. Biochem. Parasitol., 29, 55-60.
66. Schepers, H., Brasseur, R., Goormaghtigh, E., Duquenoy, P., and Ruysschaert, J.M. (1988) Mode of insertion of praziquantel and derivatives into lipid membranes. Biochem. Pharmacol., 37, 1615-1623.
67. Sabah, A.A., Fletcher, C., Webbe, G., and Doenhoff, M.J. (1985) Schistosoma mansoni-reduced efficacy of chemotherapy in infected T-cell deprived mice. Exp. Parasitol., 60, 348-354.
68. Brindley, P.J. and Sher, A. (1987) The chemotherapeutic effect of praziquantel against Schistosoma mansoni is dependent on host antibody response. J. Immunol., 139, 215-220.
69. Doenhoff, M.J., Sabah, A.A., Fletcher, C., Webbe, G., and Bain, J. (1987) Evidence of an immune-dependent action of praziquantel on Schistosoma mansoni in mice. Trans. R. Soc. Trop. Med. Hyg., 81, 947-951.
70. Karanja, D.H.S., Boyer, A.E., Strand, M., Colley, D.G., Nahlen, B.L., Ouma, J.H., and Secor, W.E. (1998) Studies on schistosomiasis in western Kenya: II. Efficacy of praziquantel for treatment of schistosomiasis in persons coinfected with human immunodeficiency virus-1. Am. J. Trop. Med. Hyg., 59, 307-311.
71. Kallestrup, P., Zinyama, R., Gomo, E., Butterworth, A.E., van Dam, G.J., Gerstoft, J., Erikstrup, C., and Ullum, H. (2006) Schistosomiasis and HIV in rural Zimbabwe: efficacy of treatment of schistosomiasis in individuals with HIV coinfection. Clin. Infect. Dis., 42, 1781-1789.
72. Wegner, D.H. (1984) The profile of the trematodicidal compound praziquantel. Arzneimittelforschung, 34, 1132-1136.
73. Craig, P. and Ito, A. (2007) Intestinal cestodes. Curr. Opin. Infect. Dis., 20, 524-532.
74. Bale, J.F. Jr (2000) Cysticercosis. Curr. Treat. Options Neurol., 2, 355-360.
75. Overbosch, D. (1992) Neurocysticercosis. An introduction with special emphasis on new developments in pharmacotherapy. Schweiz. Med. Wochenschr., 122, 893-898.
76. Cobo, F., Yarnoz, C., Sesma, B., Fraile, P., Aizcorbe, M., Trujillo, R., Diaz-de-Liano, A., and Ciga, M.A. (1998) Albendazole plus praziquantel versus albendazole alone as a preoperative treatment in intra-abdominal hydatisosis caused by Echinococcus granulosus. Trop. Med. Int. Health, 3, 462-466.
77. Andrews, P., Thomas, H., Pohlke, R., and Seubert, J. (1983) Praziquantel. Med. Res. Rev., 3, 147-200.
78. Ronketti, F., Ramana, A.V., Chao-Ming, X., Pica-Mattoccia, L., Cioli, D., and Todd, M.H. (2007) Praziquantel derivatives I: modification of the aromatic ring. Bioorg.Med. Chem. Lett., 17, 4154-4157.
79. Dong, Y., Chollet, J., Vargas, M., Mansour, N.R., Bickle, Q., Alnouti, Y., Huang, J. et al. (2010) Praziquantel analogs with activity against juvenile Schistosoma mansoni. Bioorg. Med. Chem. Lett., 20, 2481-2484.
80. Laurent, S.A.-L., Boissier, J., Coslédan, F., Gornitzka, H., Robert, A., andMeunier, B. (2008) Synthesis of.Trioxaquantel. derivatives as potential new antischistosomal drugs. Eur. J. Org. Chem., 2008, 895-913.
81. Mandour, M.E., el Turabi, H., Homeida, M.M., el Sadig, T., Ali, H.M., Bennett, J.L., Leahey, W.J., and Harron, D.W. (1990) Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis. Trans. R. Soc. Trop. Med. Hyg., 84, 389-393.
82. Wu, M.H., Wei, C.C., Xu, Z., Yuan, H.C., Lian, W.N., Yang, Q.J., Chen, M. et al. (1991) Comparison of the therapeutic efficacy and side effects of a single dose of levopraziquantel with mixed isomer praziquantel in 278 cases of schistosomiasis japonica. Am. J. Trop. Med. Hyg., 45, 345-349.
83. Meyer, T., Sekljic, H., Fuchs, S., Bothe, H., Schollmeyer, D., and Miculka, C. (2009) Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment. PLoS Negl. Trop. Dis., 3, e357.
84. Fleming, F.M., Fenwick, A., Tukahebwa, E.M., Lubanga, R.G., Namwangye, H., Zaramba, S., and Kabatereine, N.B. (2009) Process evaluation of schistosomiasis control in Uganda, 2003 to 2006: perceptions, attitudes and constraints of a national programme. Parasitology, 136, 1759-1769.
85. Woelfle, M., Seerden, J.-P., de Gooijer, J., Pouwer, K., Olliaro, P., and Todd, M.H. (2011) Resolution of Praziquantel. PLoS Negl. Trop. Dis., 5, e1260. (DOI:10.1371/ journal.pntd.0001260).